BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
Portfolio Pulse from
BeyondSpring Inc. (NASDAQ: BYSI) announced the sale of a portion of its equity interest in SEED Therapeutics for $35.4 million. The proceeds will be used to advance its lead asset, Plinabulin, into anti-cancer registrational studies.
January 28, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeyondSpring Inc. is selling part of its equity in SEED Therapeutics for $35.4 million to fund the advancement of Plinabulin into anti-cancer studies. This strategic move could enhance the company's focus on its core cancer therapy development.
The sale of equity in SEED Therapeutics provides BeyondSpring with significant capital to advance its lead asset, Plinabulin, into critical anti-cancer studies. This move is likely to be viewed positively by investors as it shows a strategic focus on core assets and potential future growth in the cancer therapy market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100